Cargando…

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients

Clinical data indicate that prognostic stratification of radically resected colorectal cancer based on disease stage only may not be always be adequate. Preclinical findings suggest that cancer stem cells may influence the biological behaviour of colorectal cancer independently from stage: objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giampieri, Riccardo, Scartozzi, Mario, Loretelli, Cristian, Piva, Francesco, Mandolesi, Alessandra, Lezoche, Giovanni, Prete, Michela Del, Bittoni, Alessandro, Faloppi, Luca, Bianconi, Maristella, Cecchini, Luca, Guerrieri, Mario, Bearzi, Italo, Cascinu, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762853/ https://www.ncbi.nlm.nih.gov/pubmed/24023782 http://dx.doi.org/10.1371/journal.pone.0072843

Ejemplares similares

Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach
por: Bittoni, Alessandro, et al.
Publicado: (2013)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
por: Scartozzi, Mario, et al.
Publicado: (2012)

Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients
por: Scartozzi, Mario, et al.
Publicado: (2012)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
por: Bianconi, Maristella, et al.
Publicado: (2019)

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
por: Demurtas, Laura, et al.
Publicado: (2017)

Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer
por: Madeddu, Clelia, et al.
Publicado: (2019)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

Optimal management of resected gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2018)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
por: Scartozzi, Mario, et al.
Publicado: (2009)

An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
por: Bittoni, Alessandro, et al.
Publicado: (2021)

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
por: Lai, Eleonora, et al.
Publicado: (2021)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
por: Giampieri, Riccardo, et al.
Publicado: (2017)

Results of Medium Seventeen Years' Follow-Up after Laparoscopic Choledochotomy for Ductal Stones
por: Quaresima, Silvia, et al.
Publicado: (2016)

An intronic mutation in MLH1 associated with familial colon and breast cancer
por: Bianchi, F., et al.
Publicado: (2010)

Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer
por: Minardi, Daniele, et al.
Publicado: (2015)

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
por: Berardi, Rossana, et al.
Publicado: (2010)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Mastectomy with one-stage or two-stage reconstruction in breast cancer: analysis of early outcomes and patient’s satisfaction
por: Gurrado, Angela, et al.
Publicado: (2022)

Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients
por: Scartozzi, M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_nri9invbmfiig36svvmcni72e3